JP2014510751A - 新規なオキサゾリジノン誘導体およびそれを含む医薬組成物 - Google Patents
新規なオキサゾリジノン誘導体およびそれを含む医薬組成物 Download PDFInfo
- Publication number
- JP2014510751A JP2014510751A JP2014502469A JP2014502469A JP2014510751A JP 2014510751 A JP2014510751 A JP 2014510751A JP 2014502469 A JP2014502469 A JP 2014502469A JP 2014502469 A JP2014502469 A JP 2014502469A JP 2014510751 A JP2014510751 A JP 2014510751A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- mmol
- preparation
- nmr
- mhz
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 *Nc(cc1)ncc1Br Chemical compound *Nc(cc1)ncc1Br 0.000 description 4
- KMAYTFAWTIDPFR-INIZCTEOSA-N O=C1O[C@@H](C[n]2nncc2)CN1c(cc1)cc(F)c1-c(cc1)cnc1N1C=NNCC1 Chemical compound O=C1O[C@@H](C[n]2nncc2)CN1c(cc1)cc(F)c1-c(cc1)cnc1N1C=NNCC1 KMAYTFAWTIDPFR-INIZCTEOSA-N 0.000 description 2
- XVJJZQCIUWSVRN-QMMMGPOBSA-N Bc(ccc(N(C[C@H](CNC(OC)=O)O1)C1=O)c1)c1F Chemical compound Bc(ccc(N(C[C@H](CNC(OC)=O)O1)C1=O)c1)c1F XVJJZQCIUWSVRN-QMMMGPOBSA-N 0.000 description 1
- ZHXUWDPHUQHFOV-UHFFFAOYSA-N Brc(cc1)cnc1Br Chemical compound Brc(cc1)cnc1Br ZHXUWDPHUQHFOV-UHFFFAOYSA-N 0.000 description 1
- XFKOJUMFSDOSGO-UHFFFAOYSA-N Brc1ccc(C2=NOCCN2)nc1 Chemical compound Brc1ccc(C2=NOCCN2)nc1 XFKOJUMFSDOSGO-UHFFFAOYSA-N 0.000 description 1
- OZPFVBLDYBXHAF-UHFFFAOYSA-N CC(C)(OC1)OC1C(O)=O Chemical compound CC(C)(OC1)OC1C(O)=O OZPFVBLDYBXHAF-UHFFFAOYSA-N 0.000 description 1
- ZEMNUBZLJDZTGA-KRWDZBQOSA-N CC(NC[C@@H](CN1c2ccc(-c(cc3)cnc3N3C=NN(C)CC3)c(F)c2)OC1=O)=O Chemical compound CC(NC[C@@H](CN1c2ccc(-c(cc3)cnc3N3C=NN(C)CC3)c(F)c2)OC1=O)=O ZEMNUBZLJDZTGA-KRWDZBQOSA-N 0.000 description 1
- WHQOGTODCZDKSG-INIZCTEOSA-N CC(NC[C@@H](CN1c2ccc(-c(cc3)cnc3N3C=NNCC3)c(F)c2)OC1=O)=O Chemical compound CC(NC[C@@H](CN1c2ccc(-c(cc3)cnc3N3C=NNCC3)c(F)c2)OC1=O)=O WHQOGTODCZDKSG-INIZCTEOSA-N 0.000 description 1
- ZKVDTSRQQGGCJW-KRWDZBQOSA-N CNC(N(CC1)N=CN1c(cc1)ncc1-c(ccc(N(C[C@H](C[n]1nncc1)O1)C1=O)c1)c1F)=O Chemical compound CNC(N(CC1)N=CN1c(cc1)ncc1-c(ccc(N(C[C@H](C[n]1nncc1)O1)C1=O)c1)c1F)=O ZKVDTSRQQGGCJW-KRWDZBQOSA-N 0.000 description 1
- RYTREWILXDQWOQ-AWEZNQCLSA-N COC(NC[C@@H](CN1c2ccc(-c(cc3)cnc3C3=NOCCN3)c(F)c2)OC1=O)=O Chemical compound COC(NC[C@@H](CN1c2ccc(-c(cc3)cnc3C3=NOCCN3)c(F)c2)OC1=O)=O RYTREWILXDQWOQ-AWEZNQCLSA-N 0.000 description 1
- RGRATWZYFIDITR-UHFFFAOYSA-N CS(OCC(CN1c(cc2F)ccc2Br)OC1=O)(=O)=O Chemical compound CS(OCC(CN1c(cc2F)ccc2Br)OC1=O)(=O)=O RGRATWZYFIDITR-UHFFFAOYSA-N 0.000 description 1
- DBGBKSKACIDLDA-ATVHPVEESA-N Fc1cc(N(C2)CO/C2=C\[n]2nncc2)ccc1-c(cc1)cnc1N1C=NNCC1 Chemical compound Fc1cc(N(C2)CO/C2=C\[n]2nncc2)ccc1-c(cc1)cnc1N1C=NNCC1 DBGBKSKACIDLDA-ATVHPVEESA-N 0.000 description 1
- ZKACSASZOABOHJ-DIMJTDRSSA-N N=CN(CCNC(C(CO)O)=O)c(cc1)ncc1-c(ccc(N(C[C@H](CNC1=N[O]=CC1)O1)C1=O)c1)c1F Chemical compound N=CN(CCNC(C(CO)O)=O)c(cc1)ncc1-c(ccc(N(C[C@H](CNC1=N[O]=CC1)O1)C1=O)c1)c1F ZKACSASZOABOHJ-DIMJTDRSSA-N 0.000 description 1
- GSDHVBHCSCQWOB-INIZCTEOSA-N NC(N(CC1)N=CN1c(cc1)ncc1-c(ccc(N(C[C@H](C[n]1nncc1)O1)C1=O)c1)c1F)=O Chemical compound NC(N(CC1)N=CN1c(cc1)ncc1-c(ccc(N(C[C@H](C[n]1nncc1)O1)C1=O)c1)c1F)=O GSDHVBHCSCQWOB-INIZCTEOSA-N 0.000 description 1
- HQIKZQXKXWQZSZ-KRWDZBQOSA-N OCC(N(CC1)N=CN1c(cc1)ncc1-c(ccc(N(C[C@H](C[n]1nncc1)O1)C1=O)c1)c1F)=O Chemical compound OCC(N(CC1)N=CN1c(cc1)ncc1-c(ccc(N(C[C@H](C[n]1nncc1)O1)C1=O)c1)c1F)=O HQIKZQXKXWQZSZ-KRWDZBQOSA-N 0.000 description 1
- AONZIQYJELDBQX-UHFFFAOYSA-N OCCNc(cc1)ncc1Br Chemical compound OCCNc(cc1)ncc1Br AONZIQYJELDBQX-UHFFFAOYSA-N 0.000 description 1
- UGBKYDASQNOIHP-SSDOTTSWSA-N OC[C@@H](CN1c(cc2)cc(F)c2Br)OC1=O Chemical compound OC[C@@H](CN1c(cc2)cc(F)c2Br)OC1=O UGBKYDASQNOIHP-SSDOTTSWSA-N 0.000 description 1
- YOUDFAYXHRAASW-UHFFFAOYSA-O [NH3+]CCN(C=N)c(cc1)ncc1-c(c(F)c1)ccc1N(CC(CNC1=N[O]=CC1)O1)C1=O Chemical compound [NH3+]CCN(C=N)c(cc1)ncc1-c(c(F)c1)ccc1N(CC(CNC1=N[O]=CC1)O1)C1=O YOUDFAYXHRAASW-UHFFFAOYSA-O 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more nitrogen atoms in the same ring, e.g. oxadiazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
式(1)中、RおよびQは、詳細な説明に定義されたものと同一である。
それに加えて、開示されているのは、式(1)で示される新規なオキサゾリジノン誘導体、そのプロドラッグ、その水和物、その溶媒和物、その異性体、またはその薬学的に許容可能な塩を活性成分として含む、抗生物質の医薬組成物である。
新規なオキサゾリジノン誘導体、そのプロドラッグ、その水和物、その溶媒和物、その異性体、およびその薬学的に許容可能な塩は、耐性細菌に対する広い抗細菌スペクトル、低い毒性、並びにグラム陽性およびグラム陰性の細菌に対する強い抗細菌効果を有するので、抗生物質として効果的に使用しうる。
【選択図】なし
Description
R1は、水素、C1〜C6アルキル、またはC3〜C6シクロアルキルであり、
R2は、水素、C1〜C6アルキル、または(CH2)mC(=O)R21(ここで、R21は、水素、(CH2)nNHR211(ここで、R211は、水素またはC1〜C6アルキルである)、CH2OH、またはCH(OH)CH2OHである)であり、かつmおよびnは、それぞれ独立して、0〜3の整数であり、かつ
Qは、OR3、NHR3、または
<反応スキーム3>
1H NMR(600MHz、CDCl3)δ8.32(d,J=2.4Hz,1H)、7.97(s,1H)、7.90(d,J=9.0Hz,1H)、7.75(dd,J1=9.0Hz,J2=2.4Hz,1H)、1.55(s,9H)
1H NMR(600MHz、CDCl3)δ8.38(d,J=1.8Hz,1H)、7.70(dd,J1=8.4Hz,J2=2.4Hz,1H)、7.66(d,J=8.4Hz,1H)、5.93(m,1H)、5.12(m,2H)、4.53(m,2H) 1.50(s,9H)
1H NMR(600MHz、CDCl3)δ8.39(d,J=2.4Hz,1H)、7.71(dd,J1=9.0Hz,J2=2.4Hz,1H)、7.60(d,J=9.0Hz,1H)、6.52(s,1H)、4.01(m,1H)、4.03(t,J=6.0Hz,2H)、3.07(t,J=6.0Hz,2H) 1.52(s,9H)、1.46(s,9H)
1H NMR(600MHz、CDCl3)δ8.59(s,1H)、8.37(d,J=2.4Hz,1H)、7.82(s,1H)、7.78(dd,J1=9.0Hz,J2=2.4Hz,1H)、6.80(d,J=9.0Hz,1H)、4.00(t,J=5.4Hz 2H)、3.85(t,J=5.4Hz,2H)
1H NMR(600MHz、CDCl3)δ7.36(m,5H)、5.15(s,1H)、5.11(s,2H)、3.73(m,2H)、3.37(m,2H)、2.08(s,1H)
1H NMR(600MHz、CDCl3)δ7.32(m,5H)、6.17(s,1H)、5.47(s,1H)、5.14(s,1H)、5.10(s,2H)、3.29(m,2H)、2.90(m,2H)、1.45(s,9H)
1H NMR(600MHz、CDCl3)δ7.35(m,5H)、7.25(d,J=8.4Hz,2H)、6.87(d,J=8.4Hz,2H)、5.99(s,1H)、5.38(s,1H)、3.92(s,2H)、3.81(s,3H)、3.29(m,2H)、2.79(m,2H)、1.40(s,9H)
1H NMR(600MHz、CDCl3)δ8.07(s,1H)、7.43(d,J=7.8Hz,1H)、7.23(d,J=8.4Hz,2H)、6.85(d,J=8.4Hz,2H)、6.42(d,J=7.8Hz,1H)、5.72(s,1H)、5.39(s,1H)、3.92(s,2H)、3.82(s,3H)、3.40(m,2H)、2.88(m,2H)、1.40(s,9H)
1H NMR(600MHz、CDCl3)δ8.29(d,J=3.0Hz,1H)、7.87(s,1H)、7.67(dd,J1=9.0Hz,J2=2.4Hz,1H)、7.32(d,J=8.4Hz,2H)、6.89(d,J=8.4Hz,2H)、6.65(d,J=9.0Hz,1H)、4.09(s,2H)、3.81(s,3H)、3.79(t,J=5.4Hz,2H)、2.92(t,J=5.4Hz,2H)
1H NMR(400MHz、CDCl3)δ8.10(d,J=1.6Hz,1H)、7.45(dd,J1=8.8Hz,J2=2.4Hz,1H)、6.33(d,J=8.8Hz)、4.95(brs,1H)、3.34(q,J=6Hz,2H)、2.94(t,J=6Hz,2H)
1H NMR(400MHz、CDCl3)δ8.09(d,J=1.6Hz,1H)、7.44(dd,J1=8.8 Hz,J2=2.4Hz,1H)、6.33(d,J=8.8Hz,1H)、4.94(brs,1H)、3.44(m,2H)、3.35(m,2H)、1.44(s,9H)
1H NMR(600MHz、CDCl3)δ8.18(m,1H)、7.65(m,2H)、7.15(m,1H)、5.80(brs,1H)、4.04(m,2H)、3.57(m,2H)、1.32(s,9H)
1H NMR(600MHz、CD3OD)δ8.20(d,J=2.4Hz,1H)、8.12(dd,J1=9.6Hz,J2=2.4Hz,1H)、7.30(d,J=9.6Hz,1H)、4.06(t,J=6.6Hz,2H)、3.40(t,J=6.6Hz,2H)
1H NMR(400MHz、CDCl3)δ8.49(s,1H)、8.20(s,1H)、7.65(dd,J1=9.2Hz,J2=2.4Hz,1H)、7.33(d,J=9.0Hz,1H)、7.24(s,1H)、4.07(t,J=5.2Hz,2H)、3.90(t,J=5.2Hz,2H)
1H NMR(600MHz、CDCl3)δ8.09(s,1H)、7.43(m,1H)、6.31(d,J=8.4Hz,1H)、5.26(brs,1H)、, 3.43(m,4H)、3.22(m,2H)、1.45(s,9H)、1.10(t,J=6.6Hz,1H)
1H NMR(600MHz、DMSOd−6)δ8.24(s,1H)、7.96(s,1H)、7.09(d,J=9Hz,1H)、3.85(m,2H)、3.40(m,2H)、3.09(m,2H)、1,39〜1.30(m,9H)、1.01(t,J=6.6Hz,1H)
1H NMR(400MHz、DMSOd−6)δ9.20(brs,1H)、8.29(d,J=2Hz,1H)、7.98(dd,J1=9.2Hz,J2=2.4Hz,1H)、7.32(d,J=9.2Hz,1H)、4.04(t,J=6.4Hz,1H)、3.27(t,J=6.4Hz,1H)、2.97(q,J=7.2Hz,1H)、1.21(t,J=7.2Hz,1H)
1H NMR(600MHz、CDCl3)δ8.11(d,J=1.8Hz,1H)、7.55(dd,J1=9Hz,J2=2.4Hz,1H)、7.19(d,J=9Hz,1H)、6.72(s,1H)、3.98(t,J=4.8Hz,2H)、3.39(t,J=4.8Hz,2H)、3.17(q,J=7.2Hz,2H)、1.18(t,J=7.2Hz,2H)
1H NMR(400MHz、CDCl3)δ8.08(d,J=1.6Hz,1H)、7.46(dd,J1=8.8Hz,J2=1.6Hz,1H)、6.37(d,J=8.8Hz)、4.87(s,1H)、3.81(t,J=4.4Hz,2H)、3.65(s,1H)、3.45(m,2H)
1H NMR(600MHz、CDCl3)δ8.10(d,J=2.4Hz,1H)、7.85(m,2H)、7.78(m,2H)、7.46(dd,J1=9.0Hz,J2=2.4Hz,1H)、6.47(dd,J1=8.4Hz,J2=0.6Hz,1H)、5.62(m,1H)、4.37(t,J=4.8Hz,2H)、3.70(m,2H)
1H NMR(400MHz、CDCl3)δ8.10(dd,J1=2.8Hz,J2=0.8Hz,1H)、7.46(dd,J1=8.8Hz,J2=2.4Hz,1H)、6.33(dd,J1=8.8Hz,J2=0.4Hz,1H)、3.86(t,J=4.8Hz,2H)、3.52(m,2H)
1H NMR(600MHz、CDCl3)δ8.39(s,1H)、8.35(dd,J1=2.4Hz,J2=0.6Hz,1H)、7.78(dd,J1=13.8Hz,J2=2.4Hz,1H)、6.73(dd,J1=9.0Hz,J2=0.6Hz,1H)、4.21(t,J=4.8Hz,2H)、3.83(t,J=4.8Hz,2H)
1H NMR(600MHz、CDCl3)δ7.84(brs,2H)、7.76(brs,2H)、4.34(d,J=15.0Hz,2H)、3.63(brs,2H)、3.04(d,J=15.0Hz,3H)、1.46(d,J=16.2Hz,9H)
1H NMR(600MHz,CDCl3)δ7.84(brs,2H)、7.76(brs,2H)、4.34(d,J=15.0Hz,2H)、3.63(brs,2H)、3.04(d,J=15.0Hz,3H)、1.46(d,J=16.2Hz,9H)
1H NMR(600MHz、DMSO−d6)δ9.31(brs,1H)、7.88−7.92(m,4H)、4.46(t,J=5.4Hz,2H)、3.30(t,J=5.4Hz,2H)、2.66(s,3H)
1H NMR(600MHz、DMSO−d6)δ3.74(t,J=4.8Hz,2H)、3.08(t,J=4.8Hz,2H)、2.54(s,3H)、
1H NMR(600MHz、CDCl3)δ8.80(dd,J1=2.4Hz,J2=0.6Hz,1H)、8.00(dd,J1=8.4Hz,J2=1.8Hz,1H)、7.60(dd,J1=8.4Hz,J2=1.2Hz,1H)
1H NMR(600MHz、CDCl3)δ8.57(d,J=2.4Hz)、7.94(dd,J1=8.4Hz,J2=0.6Hz,1H)、7.85(dd,J1=8.4Hz,J2=2.4Hz,1H)、6.43(m,1H)、4.06(t,J=4.8Hz,2H)、3.83(m,2H)
1H NMR(600MHz、CDCl3)δ8.70(d,J=2.4Hz)、7.89(dd,J1=8.4Hz,J2=2.4Hz,1H)、7.56(d,J=8.4Hz,1H)、4.14(t,J=4.8Hz,2H)、3.48(t,J=4.8Hz,2H)、2.88(s,3H)
1H NMR(600MHz、CDCl3)δ7.40(m,7H)、6.93(dd,J1=9.0Hz,J2=2.4Hz,1H)、6.71(s,1H)、5.20(s,2H)
1H NMR(600MHz、CDCl3)δ7.53(m,2H)、7.15(dd,J1=9.0Hz,J2=2.4Hz,1H)、4.77(m,1H)、4.00(m,3H)、3.77(m,1H)、2.10(t,J=6.0Hz,1H)
1H NMR(400MHz、CDCl3)δ11.25(bs,1H)、8.52(d,J=2.0Hz,1H)、6.07(d,J=2.0Hz,1H)
1H NMR(400MHz、CDCl3)δ8.16(d,J=2.0Hz,1H)、7.55(m,2H)、7.18(m,1H)、6.01(d,J=2.0Hz,1H)、5.03(m,1H)、4.59(dd,J1=11.6Hz,J2=4.0Hz,1H)、4.51(dd,J1=11.6Hz,J2=4.4Hz,1H)、4.16(t,J=8.8Hz,1H)、3.97(dd,J1=8.8Hz,J2=6.0Hz,1H)
1H NMR(400MHz、CDCl3)δ7.53(m,2H)、7.14(dd,J1=8.8Hz,J2=2.4Hz,1H)、4.95(m,1H)、4.46(m,2H)、4.13(dd,J1=9.2Hz,J2=9.2Hz,1H)、3.94(dd,J1=9.2Hz,J2=6.4Hz,1H)、3.10(s,3H)
1H NMR(600MHz、CDCl3)δ8.26(d,J=1.8Hz,1H)、7.53(m,2H)、7.14(dd,J=9.0Hz,J=3.0Hz,1H)、6.01(br, 1H)、5.92(m,1H)、4.37(dd,J=7.8Hz,1H)、4.12(m,2H)、3.81(dd,J=8.4Hz,J=4Hz,1H)、1.56(s,9H)
1H NMR(600MHz、CDCl3)δ7.53(m,2H)、7.15(dd,J1=9.0Hz,J2=2.4Hz,1H)、4.80(m,1H)、4.06(dd,J1=9.0Hz,J2=9.0Hz,1H)、3.84(dd,J1=9.0Hz,J2=6.0Hz,1H)、3.73(dd,J1=13.2Hz,J2=4.8Hz,1H)、3.61(dd,J1=13.2Hz,J2=4.8Hz,1H)
1H NMR(600MHz、DMSO)δ8.26(t,J=6.0Hz,1H)、7.72(t,J=8.4Hz,1H)、7.65(dd,J1=12.0Hz,J2=2.4Hz,1H)、7.32(dd,J1=8.4Hz,J2=3.6Hz,1H)、4.74(m,1H)、4.12(dd,J1=9.0Hz,J2=9.0Hz,1H)、3.73(dd,J1=9.0Hz,J2=6.6Hz,1H)、3.42(t,J=5.4Hz,2H)、1.83(s,3H)
1H NMR(600MHz、CDCl3)δ7.53(m,2H)、7.11(dd,J1=9.0Hz,J2=2.4Hz,1H)、5.11(s,1H)、4.78(m,1H)、4.04(dd,J1=9.0Hz,J2=9.0Hz,1H)、3.80(m,1H)、3.68(s,3H)、3.61(m,2H)
1H NMR(600MHz、CDCl3)δ7.78(d,J=1.2Hz,1H)、7.75(d,J=1.2Hz,1H)、7.49(dd,J1=8.4Hz,J2=7.8Hz,1H)、7.42(dd,J1=10.8Hz,J2=2.4Hz,1H)、7.00(dd,J1=9.0Hz,J2=2.4Hz,1H)、5.08(m,1H)、4.80(dd,J1=4.2Hz,J2=1.2Hz,2H)、4.15(dd,J1=9.6Hz,J2=9,6Hz,1H)、3.94(dd,J1=9.6Hz,J2=6.6Hz,1H)
1H NMR(600MHz、CDCl3)δ8.16(d,J=1.8Hz,1H)、7.44(dd,J1=8.4Hz,J2=1.2Hz,1H)、)、7.41(dd,J1=11.4Hz,J2=1.8Hz,1H)、)、7.28(dd,J1=7.8Hz,J2=1.8Hz,1H)、6.00(d,J=1.8Hz,1H)、5.04(m,1H)、4.59(m,1H)、4.05(m,1H)、4.18(t,J=9.0Hz,1H)、3.99(dd,J1=9.0Hz,J2=6.6Hz,1H)、1.36(s,12H)
1H NMR(600MHz、CDCl3)δ7.78(d,J=1.2Hz,1H)、7.45(d,J=1.2Hz,1H)、7.70(dd,J1=8.4Hz,J2=7.2Hz,1H)、7.31(dd,J1=11.4Hz,J2=1.8Hz,1H)、7.12(dd,J1=8.4Hz,J2=1.8Hz,1H)、5.07(m,1H)、4.79(m,2H)、4.18(dd,J1=9.0Hz,J2=9.0Hz,1H)、3.93(dd,J1=9.0Hz,J2=5.4Hz,1H)、1.32(s,12H)
1H NMR(600MHz、CDCl3)δ8.26(d,J=0.6Hz,1H)、7.23(dd,J1=7.8Hz,J2=7.8Hz,1H)、7.39(dd,J1=11.4Hz,J2=1.2Hz,1H)、7.25(dd,J1=8.4Hz,J2=1.2Hz,1H)、6.92(br,1H)、5.09(m,1H)、4.38(dd,J1=8.4Hz,J2=8.4Hz,1H)、4.12(dd,J1=8.4Hz,2H)、3.82(dd,J1=8.4Hz,J2=5.4Hz,1H)、1.36(s,9H)、1.26(s,12H)
1H NMR(600 MHz、CDCl3)δ7.24(dd,J1=8.4Hz,J2=8.4Hz,1H),)、7.39(dd,J1=11.4Hz,J2=1.2Hz,1H)、7.23(dd,J1=8.4Hz,J2=1.8Hz,1H)、5.14(m,1H)、4.78(m,1H)、4.07(dd,J1=9.0Hz,J2=9.0Hz,1H)、3.81(m,1H)、3.68(s,3H)、3.62(m,1H)、3.54(m,1H)、1.36(s,12H)
1H NMR(600MHz、CDCl3)δ7.45(dd,J1=8.4Hz,J2=8.4Hz,1H)、7.43(dd,J1=10.8Hz,J2=1.8Hz,1H)、7.29(dd,J1=7.8Hz,J2=1.8Hz,1H)、4.77(m,1H)、4.01(m,3H)、3.78(m,1H)、2.10(t,J=5.4Hz,1H)、1.37(s,12H)
1H NMR(600MHz、DMSOd−6)δ8.52(s,1H)、8.50(s,1H)、8.28(t,J=6.0Hz,1H)、8.06(s,1H)、8.10(d,J=9.0Hz)、7.63(m,2H)、7.43(dd,J1=8.4Hz,J2=2.4Hz)、7.36(d,J=8.4Hz,1H)、4.76(m,1H)、4.17(t,J=9.0Hz,1H)、4.18(t,J=7.8Hz,2H)、3.92(m,4H)、3.78(dd,J1=9.0Hz,J2=6.6Hz,1H)、3.44(t,J=6.0Hz,2H)、1.84(s,3H)
LCMS:C21H21FN6O4に対して441(M+H+)
1H NMR(600MHz、DMSOd−6)δ9.00(s,1H)、8.62(s,1H)、8.30(t,J=6.0Hz,1H)、8.14(d,J=9.0Hz,1H)、7.68(dd,J1=9.0Hz,J2=9.0Hz,1H)、7.65(dd,J=7.8Hz,J2=2.4Hz,1H)、7.57(d,J=8.4Hz,1H)、7.46(dd,J1=9.0Hz,J2=2.4Hz,1H)、4.78(m,1H)、4.19(t,J=9.0Hz,1H)、4.03(t,J=4.8Hz,2H)、3.79(dd,J1=9.0Hz,J2=6.6Hz,1H)、3.44(m,4H)、1.84(s,3H)
LCMS:C20H21FN6O3に対して413(M+H+)
1H NMR(600MHz、DMSOd−6)δ8.44(s,1H)、8.25(t,J=6.0Hz,1H)、7.95(s,1H)、7.92(d,J=9.6Hz,1H)、7.61(m,2H)、7.41(dd,J1=9.0Hz,J2=2.4Hz,1H)、7.16(d,J=8.4Hz,1H)、4.76(m,1H)、4.17(dd,J1=9.0Hz,J2=9.0Hz,1H)、3.84(t,J=5.4Hz,2H)、3.79(dd,J1=9.0Hz,J2=6.0Hz,1H)、3.43(t,J=5.4Hz,2H)、2.95(t,J=5.4Hz,2H)、2.68(s,3H)、1.84(s,3H)
LCMS:C21H23FN6O3に対して427(M+H+)
1H NMR(400MHz、CDCl3)δ8.45(s,1H)、8.00(s,1H)、7.81(d,J=8.8Hz,1H)、7.56(dd,J1=13.2Hz,J2=2.4Hz,1H)、7.43(dd,J1=8.8Hz,J2=8.8Hz,1H)、7.32(dd,J1=9.2Hz,J2=2.4Hz,1H)、6.87(d,J=8.8Hz,1H)、6.09(t,J=5.6Hz,1H)、4.84(m,1H)、4.11(dd,J1=8.8Hz,J2=8.8Hz,1H)、3.97(t,J=5.2Hz,2H)、3.84(dd,J1=9.2Hz,J2=5.6Hz,1H)、3.69(m,2H)、3.08(t,J=5.6Hz,2H)、3.04(m,2H)、2.06(s,3H)、1.28(t,J=7.2Hz,3H)
LCMS:C22H25FN6O3に対して441(M+H+)
1H NMR(600MHz、CDCl3)δ8.45(s,1H)、7.98(s,1H)、7.81(d,J=9.0Hz,1H)、7.56(dd,J1=12.6Hz,J2=2.4Hz,1H)、7.42(t,J=8.4Hz,1H)、7.29(m,1H)、6.87(d,J=9.0Hz,1H)、6.08(t,J=6.6Hz,1H)、4.83(m,1H)、4.25(q,J=7.2Hz,2H)、4.10(m,1H)、3.99(t,J=5.4Hz,2H)、3.84(s,2H)、3.75(m,1H)、3.72(m,1H)、3.66(m,1H)、3.03(t,J=5.4Hz,2H)、2.05(s,3H)、1.32(t,J=7.2Hz,3H)
LCMS:C24H27FN6O5に対して499(M+H+)
1H NMR(600MHz、CDCl3)δ8.44(s,1H)、8.02(s,1H)、7.82(d,J=8.4Hz,1H)、7.56(dd,J1=12.6Hz,J2=1.8Hz,1H)、7.41(t,J=8.4Hz,1H)、7.29(m,1H)、6.87(d,J=9.0Hz,1H)、6.17(t,J=6.6Hz)、4.83(m,1H)、3.99(m,2H)、3.97(t,J=5.4Hz,1H)、3.84(m,1H)、3.73(m,1H)、3.69(m,1H)、3.50(m,2H)、3.12(m,2H)、3.06(m,2H)、2.05(s,3H)
LCMS:C22H25FN6O4に対して457(M+H+)
1H NMR(600MHz、CDCl3)δ8.43(s,1H)、7.99(s,1H)、7.79(d,J=8.4Hz,1H)、7.54(dd,J1=13.2Hz,J2=2.4Hz,1H)、7.38(t,J=9.0Hz,1H)、7.31(m,1H)、6.85(d,J=9.0Hz,1H)、6.30(t,J=6.0Hz,1H)、6.02(m,1H)、5.31(d,J=16.8Hz,1H)、5.25(d,J=9.6Hz,1H)、4.83(m,1H)、4.10(m,1H)、3.94(t,J=4.8Hz,2H)、3.84(m,1H)、3.73(m,1H)、3.72(m,1H)、3.65(m,2H)、3.12(q,J=7.2Hz,2H)、3.04(t,J=5.4Hz,2H)、2.04(s,3H)
LCMS:C23H25FN6O3に対して453(M+H+)
1H NMR(600MHz、CDCl3)δ8.45(s,1H)、8.04(s,1H)、7.89(d,J=9.6Hz,1H)、7.55(d,J=12.6Hz,1H)、7.42(t,J=8.9Hz,1H)、7.29(d,J=8.4Hz,1H)、6.88(d,J=9.0Hz,1H)、5.97(m,1H)、4.82(m,1H)、4.09(t,J=8.7Hz,1H)、3.98(m,2H)、3.88(s,2H)、3.81(t,J=7.8Hz,1H)、3.67(m,1H)、3.48(m,2H)、3.18(m,2H)、2.04(s,3H)
LCMS:C23H23FN6O3に対して451(M+H+)
1H NMR(600MHz、CDCl3)δ8.43(s,1H)、7.95(s,1H)、7.80(d,J=8.4Hz,1H)、7.55(dd,J1=12.6Hz,J2=1.8Hz,1H)、7.41(t,J=8.7Hz,1H)、7.28(dd,J1=9.0Hz,J2=2.4Hz,1H)、6.86(d,J=9.0Hz,1H)、6.08(t,J=6.3Hz,1H)、4.82(m,1H)、4.09(t,J=9.0Hz,1H)、3.98(t,J=4.8Hz,2H)、3.82(dd,J1=9.6Hz,J2=7.2Hz,1H)、3.76(s,2H)、3.72(m,2H)、3.65(m,2H)、3.30(t,J=4.8Hz,2H)、2.04(s,9H)、1.50(s,9H)
LCMS:C26H31FN6O5に対して527(M+H+)
1H NMR(600MHz、DMSOd−6)δ8.52(s,1H)、8.37(bs,1H)、8.30(t,J=5.4Hz,1H)、8.02(d,J=7.8Hz,1H)、7.65(m,2H)、7.44(d,J=8.4Hz,1H)、7.34(d,J=8.4Hz,1H)、4.78(m,1H)、4.18(t,J=8.4Hz,1H)、3.96(m,2H)、3.81(s,2H)、3.79(m,2H)、3.44(m,2H)、3.34(m,1H)、1.84(s,3H)
LCMS:C22H23FN6O5に対して471(M+H+)
1H NMR(600MHz、DMSOd−6)δ8.51(s,1H)、8.27(t,J=6.0Hz,1H)、8.02(s,1H)、8.00(d,J=9.0Hz,1H)、7.64(dd,J1=9.0Hz,J2=9.0Hz,1H)、7.62(dd,J= 12.0Hz,J2=1.8Hz,1H)、7.43(dd,J1=9.0Hz,J2=1.8Hz,1H)、7.35(d,J=8.4Hz,1H)、4.78(m,1H)、4.63(t,J=6.0Hz,1H)、4.37(d,J=6.0Hz,1H)、4.17(t,J=9.0Hz,1H)、3.93(s,4H)、3.78(dd,J1=9.0Hz,J2=6.6Hz,1H)、3.44(t,J=6.6Hz,1H)、1.84(s,3H)
LCMS:C22H23FN6O5に対して471(M+H+)
1H NMR(600MHz、CDCl3)δ8.49(d,J=0.6Hz,1H)、7.91(s,1H)、7.88(dd,J1=8.4Hz,J2=1.2Hz,1H)、7.58(d,J=12.6Hz,1H)、7.42(t,J=9.0Hz,1H)、7.31(d,J=8.4Hz,1H)、6.95(d,J=9.0Hz,1H)、6.10(t,J=6.3Hz,1H)、5.13(s,2H)、4.83(m,1H)、4.10(t,J=8.4Hz,1H)、4.06(t,J=4.8Hz,2H)、3.93(t,J=5.1Hz,2H)、3.84(m,1H)、3.72(m,1H)、3.67(m,1H)、2.22(s,3H)、2.04(s,3H)
LCMS:C24H25FN6O6に対して513(M+H+)
1H NMR(600MHz、DMSOd−6)δ8.52(s,1H)、8.28(t,J=6.0Hz,1H)、8.08(d,J=5.4Hz,1H)、8.01(d,J=9.0Hz,1H)、7.64(m,2H)、7.43(d,J=8.4Hz,1H)、7.40(d,J=9.0Hz,1H)、5.04(s,1H)、4.81(s,1H)、4.77(m,1H)、4.18(t,J=9.0Hz,1H)、3.94(m,4H)、3.79(t,J=8.4Hz,1H)、3.44(t,J=5.4Hz,2H)、3.38(m,2H)、2.62(m,2H)、1.84(s,3H)
LCMS:C26H27FN6O8に対して571(M+H+)
1H NMR(600MHz、CDCl3)δ8.49(s,1H)、7.88(d,J=8.4Hz,1H)、7.86(s,1H)、7.58(dd,J1=12.6Hz,J2=2.4Hz,1H)、7.43(dd,J1=8.4Hz,J2=8.4Hz,1H)、7.35(m,11H)、6.94(d,J=7.8Hz,1H)、6.00(t,J=6.0Hz,1H)、5.18(m,4H)、5.11(d,J1=11.4Hz,1H)、4.82(m,1H)、4.11(dd,J1=9.0Hz,J2=9.0Hz,1H)、4.06(t,J=5.4Hz,2H)、3.90(s,2H)、3.82(dd,J1=9.0Hz,J2=7.2Hz,1H)、3.74(m,1H)、3.66(m,1H)、2.04(s,3H)
LCMS:C36H36FN6O8Pに対して741(M+H+)
1H NMR(600MHz、D2O)δ8.18(s,1H)、7.78(d,J=8.4Hz,1H)、7.61(s,1H)、7.29(dd,J1=8.4Hz,J2=8.4Hz,1H)、7.23(d,J=12.4Hz,1H)、7.09(d,J=8.4Hz,1H)、6.97(d,J=9.0Hz,1H)、4.58(m,3H)、4.00(dd,J1=9.0Hz,J2=9.0Hz,1H)、3.75(s,2H)、3.64(m,3H)、3.43(m,1H)、3.34(dd,J1=15.0Hz,J2=5.4Hz,1H)、1.79(s,3H)
LCMS:C22H24FN6O8Pに対して551(M+H+)
1H NMR(600MHz、DMSOd−6)δ8.49(s,1H)、8.23(t,J=6.0Hz,1H)、7.97(m,2H)、7.61(m,2H)、7.42(dd,J1=8.4Hz,J2=2.4Hz,1H)、7.29(d,J=8.4Hz,1H)、6.97(q,J=4.8Hz,1H)、4.76(m,1H)、4.17(dd,J1=9.6Hz,J2=9.6Hz,1H)、3.90(t,J= 5.4Hz,2H)、3.79(m,3H)、3.44(t,J=5.4Hz,1H)、2.67(d,J=4.2Hz,3H)、1.84(s,3H)
LCMS:C22H24FN7O4に対して470(M+H+)
1H NMR(600MHz、DMSOd−6)δ8.50(s,1H)、8.27(t,J=6.0Hz,1H)、7.98(d,J=6.0Hz,1H)、7.96(s,1H)、7.62(m,2H)、7.43(dd,J1=8.4Hz,J2=2.4Hz,1H)、7.30(d,J=9.0Hz,1H)、6.44(s,2H)、4.77(m,1H)、4.17(dd,J1=9.0Hz,J2=9.0Hz,1H)、3.90(t,J=5.4Hz,2H)、3.80(m,3H)、3.44(t,J=5.4Hz,1H)、1.84(s,3H)
LCMS:C21H22FN7O4に対して456(M+H+)
1H NMR(600MHz、DMSOd−6)δ8.52(s,1H)、8.28(t,J=6.0Hz,1H)、8.05(s,1H)、8.00(dd,J1=7.2Hz,J2=2.4Hz,1H)、7.65(dd,J1=8.4Hz,J2=8.4Hz,1H)、7.62(dd,J1=13.8Hz,J2=2.4Hz,1H)、7.43(dd,J1=8.4Hz,J2=2.4Hz,1H)、7.35(d,J=8.4Hz,1H)、6.48(t,6.0Hz,1H)、4.77(m,1H)、4.17(dd,J1=9.0Hz,J2=9.0Hz,1H)、4.05(d,J=6.0Hz,2H)、3.93(s,4H)、3.79(dd,J=9.0Hz,J2=6.0Hz,1H)、3.44(t,J=6.0Hz,2H)、1.84(s,3H)、1.38(s,9H)
LCMS:C27H32FN7O6に対して570(M+H+)
1H NMR(600MHz、DMSOd−6)δ8.53(s,1H)、8.29(t,J=6.0Hz,1H)、8.18(m,4H)、8.02(dd,J1=8.4Hz,J2=2.4Hz,1H)、7.63(m,2H)、7.44(dd,J1=13.2Hz,J2=2.4Hz,1H)、7.40(d,J=7.2Hz,1H)、6.48(t,6.0Hz,1H)、4.77(m,1H)、4.17(dd,J1=7.8Hz,J2=7.8Hz,1H)、4.00(m,4H)、3.80(m,1H)、3.45(m,4H)、1.84(s,3H)
LCMS:C22H24FN7O4に対して470(M+H+)
1H NMR(600MHz、DMSOd−6)δ8.47(s,1H)、8.23(t,J=6.0Hz,1H)、7.98(s,1H)、7.96(d,J=8.4Hz,1H)、7.60(m,2H)、7.39(dd,J1=9.0Hz,J2=1.8Hz,1H)、7.32(d,J=8.8Hz,1H)、5.18(t,6.6Hz,1H)、4.73(m,1H)、4.26(dd,J1=7.8Hz,J2=7.8Hz,1H)、4.13(t,J=9.0Hz,1H)、4.92(m,3H)、3.85(m,2H)、3.74(dd,J1=9.0Hz,J2=6.6Hz,1H)、3.40(t,J=5.4Hz,2H)、1.80(s,3H)、1.36(s,3H)、1.30(s,3H)
LCMS:C26H29FN6O6に対して541(M+H+)
1H NMR(600MHz、DMSOd−6)δ8.47(s,1H)、8.25(t,J=5.4Hz,1H)、8.00(s,1H)、7.96(d,J=9.0Hz,1H)、7.59(m,2H)、7.39(dd,J1=9.0Hz,J2=2.4Hz,1H)、7.32(d,J1=9.0Hz,1H)、4.81(m,1H)、4.72(m,1H)、4.65(m,2H)、4.13(dd,J1=9.0Hz,J2=9.0Hz,1H)、4.02(m,1H)、3.95(m,1H)、3.80(m,3H)、3.60(m,2H)、3.40(t,J=5.4Hz,2H)、1.80(s,3H)
LCMS:C22H25FN6O6に対して501(M+H+)
1H NMR(600MHz、DMSOd−6)δ8.51(m,2H)、8.06(s,1H)、8.00(d,J=8.4Hz,1H)、7.63(m,2H)、7.56(t,J=5.4Hz,1H)、7.43(dd,J1=8.4Hz,J2=1.8Hz,1H)、7.35(d,J=9.0Hz,1H)、4.76(m,1H)、4.18(t,J=8.4Hz,1H)、3.93(t,J=4.8Hz,2H)、3.88(t,J=4.8Hz,2H)、3.82(dd,J1=9.0Hz,J2=6.0Hz,1H)、3.54(s,3H)、3.38(m,2H)
LCMS:C21H21FN6O5に対して457(M+H+)
1H NMR(600MHz、DMSOd−6)δ8.51(m,2H)、8.06(s,1H)、8.00(d,J=8.4Hz,1H)、7.63(m,2H)、7.56(t,J=5.4Hz,1H)、7.43(dd,J1=8.4Hz,J2=1.8Hz,1H)、7.35(d,J=9.0Hz,1H)、4.76(m,1H)、4.18(t,J=8.4Hz,1H)、3.93(t,J=4.8Hz,2H)、3.88(t,J=4.8Hz,2H)、3.82(dd,J1=9.0Hz,J2=6.0Hz,1H)、3.54(s,3H)、3.38(m,2H)
LCMS:C21H21FN6O5に対して457(M+H+)
1H NMR(600MHz、CDCl3)δ8.45(s,1H)、7.98(s,1H)、7.81(m,1H)、7.54(dd,J1=13.2Hz,J2=2.4Hz,1H)、7.41(t,J=8.4Hz,1H)、7.31(dd,J1=8.4Hz,J2=2.4Hz,1H)、6.86(d,J=8.4Hz,1H)、5.14(m,1H)、4.81(m,1H)、4.09(t,J=8.4Hz,1H)、3.94(t,J=4.8Hz,2H)、3.85(t,J=8.4Hz,1H)、3.69(s,3H)、3.64(m,1H)、3.58(m,1H)、3.03(t,J=4.8Hz,2H)、2.84(s,3H)
LCMS:C21H23FN6O4に対して443(M+H+)
1H NMR(600MHz、CDCl3)δ8.05(s,1H)、7.93(s,1H)、7.89(d,J=8.4Hz,1H)、7.71(dd,J1=12.6Hz,J2=2.4Hz,1H)、7.43(t,J=8.4Hz,1H)、7.34(dd,J1=8.4Hz,J2=2.4Hz,1H)、6.96(d,J=7.8Hz,1H)、5.12(m,1H)、4.82(m,1H)、4.55(d,J=4.8Hz,2H)、4.11(t,J=5.4Hz,2H)、4.06(m,1H)、3.95(t,J=5.4Hz,2H)、3.87(t,J=7.8Hz,1H)、3.70(s,3H)、3.65(m,1H)、3.57(m,1H)
LCMS:C22H23FN6O6に対して487(M+H+)
1H NMR(600MHz、DMSOd−6)δ8.50(s,1H)、7.98(d,J=9.0Hz,1H)、7.95(s,1H)、7.63(m,2H)、7.56(m,1H)、7.43(d,J=9.0Hz,1H)、7.30(d,J=9.0Hz,1H)、6.44(s,2H)、4.76(m,1H)、4.18(t,J=9.6Hz,1H)、3.90(t,J=4.8Hz,2H)、3.81(m,2H)、3.54(s,3H)、3.36(m,3H)
LCMS:C21H22FN7O5に対して472(M+H+)
1H NMR (600 MHz, CDCl3) δ 8.48 (s, 1H), 7.90 (s, 1H), 7.86 (d, J = 9.0 Hz, 1H), 7.56 (d, J = 12.6 Hz, 1H), 7.42 (t, J = 9.0 Hz, 1H), 7.33 (d, J = 6.0 Hz, 1H), 6.91 (d, J = 8.4 Hz, 1H), 6.34 (d, J = 4.8 Hz, 1H), 5.14 (m, 1H), 4.81 (m, 1H), 4.10 (t, J = 8.4 Hz, 1H), 4.01 (t, J = 4.8 Hz, 2H), 3.90 (t, J = 4.8 Hz, 2H), 3.86 (t, J = 7.8 Hz, 1H), 3.69 (s, 3H), 3.64 (m, 1H), 3.58 (m, 1H), 2.91 (d, J = 4.8 Hz, 3H)
LCMS:C22H24FN7O5に対して486(M+H+)
1H NMR(400MHz、DMSOd−6)δ8.50(s,1H)、8.49(s,1H)、8.05(s,1H)、7.99(d,J=8.4Hz,1H)、7.63(m,2H)、7.45(dd,J1=8.4Hz,J2=1.8Hz,1H)、7.33(d,J=9.6Hz,1H)、5.24(t,J=5.4Hz,1H)、4.73(m,1H)、4.18(dd,J1=8.4Hz,J2=8.4Hz,1H)、3.89(m,5H)、3.67(m,1H)、3.58(m,1H)
LCMS:C19H18FN5O4に対して400(M+H+)
1H NMR(600MHz、DMSOd−6)δ8.43(s,1H)、7.94(s,1H)、7.90(d,J=9.0Hz,1H)、7.62(m,2H)、7.42(dd,J1=9.0Hz,J2=2.4Hz,1H)、7.17(d,J=8.4Hz,1H)、4.75(m,1H)、4.14(dd,J1=9.0Hz,J2=9.0Hz,1H)、3.87(dd,J1=9.0Hz,J2=6.0Hz,1H)、3.73(m,1H)、3.58(m,1H)、3.43(t,J=5.4Hz,2H)、2.97(m,4H)、1.31(t,J=5.4Hz,3H)
LCMS:C20H22FN5O3に対して400(M+H+)
1H NMR(600MHz、DMSOd−6)δ9.00(s,1H)、8.61(s,1H)、8.20(s,1H)、8.14(d,J=8.4Hz,1H)、7.78(s,1H)、7.66(t,J=9.0Hz,1H)、7.62(m,1H)、7.56(s,1H)、7.40(dd,J1=9.0Hz,J2=2.4Hz,1H)、5.19(m,1H)、4.87(d,J=4.8Hz,2H)、4.30(t,J=9.0Hz,1H)、4.03(t,J=4.8Hz,2H)、3.96(m,2H)、3.66(m,1H)、3.46(m,2H)
LCMS:C20H19FN8O2に対して423(M+H+)
1H NMR(600MHz、DMSOd−6)δ8.44(s,1H)、8.19(s,1H)、7.95(s,1H)、7.91(d,J=9.0Hz,1H)、7.77(s,1H)、7.60(t,J=8.4Hz,1H)、7.54(dd,J1=13.8Hz,J2=1.8Hz,1H)、7.36(dd,J1=8.4Hz,J2=2.4Hz,1H)、7.16(d,J=9.0Hz,1H)、5.18(m,1H)、4.86(m,1H)、4.29(t,J=9.0Hz,1H)、3.95(m,1H)、3.84(t,J=4.8Hz,2H)、2.95(t,J=4.8Hz,2H)、2.68(s,3H)
LCMS:C21H21FN8O2に対して437(M+H+)
1H NMR(600MHz、DMSOd−6)δ8.51(s,1H)、8.19(s,1H)、8.02(s,1H)、7.99(d,J=8.4Hz,1H)、7.78(s,1H)、7.62(t,J=8.4Hz,1H)、7.55(d,J=13.2Hz,1H)、7.38(d,J=8.4Hz,1H)、7.35(d,J=9.0Hz,1H)、5.19(m,1H)、4.86(d,J=4.2Hz,2H)、4.37(s,2H)、4.29(t,J=9.0Hz,1H)、3.95(m,1H)、3.93(m,4H)
LCMS:C21H22FN8O4に対して481(M+H+)
1H NMR(600MHz、DMSOd−6)δ8.49(s,1H)、8.19(s,1H)、7.97(d,J=9.0Hz,1H)、7.95(s,1H)、7.78(s,1H)、7.62(t,J=9.0Hz,1H)、7.55(d,J=13.2Hz,1H)、7.38(d,J=8.4Hz,1H)、7.30(d,J=9.0Hz,1H)、6.44(s,2H)、5.18(m,1H)、4.86(d,J=4.8Hz,2H)、4.29(t,J=9.0Hz,1H)、3.96(m,1H),3.90(t,J=4.8Hz,2H)、3.82(t,J=4.8Hz,2H)
LCMS:C21H20FN9O3に対して466(M+H+)
1H NMR(600MHz、DMSOd−6)δ8.49(s,1H)、8.19(s,1H)、7.96(m,2H)、7.78(s,1H)、7.62(t,J=9.0Hz,1H)、7.55(m,1H)、7.38(m,1H)、7.29(d,J=9.0Hz,1H)、6.97(m,1H)、5.19(m,1H)、4.86(d,J=4.8Hz,2H)、4.29(t,J=9.0Hz,1H)、3.95(m,1H)、3.90(t,J=4.8Hz,2H)、3.81(t,J=4.8Hz,2H)、2.67(d,J=4.2Hz,3H)
LCMS:C22H22FN9O3に対して480(M+H+)
1H NMR(400MHz、CDCl3)δ8.48(s,1H)、7.87(m,2H)、7.81(d,J=0.8Hz,1H)、7.77(dd,J=0.8Hz,1H)、7.45(dd,J1=8.8Hz,J2=2.4Hz,1H)、7.35(m,11H)、7.20(dd,J1=8.8Hz,J2=2.4Hz,1H)、6.94(d,J=8.8Hz,1H),5.12(m,4H)、5.14(m,3H) 4.83(d,J=4.0Hz,2H)、4.15(dd,J1=9.6Hz,J2=9.6Hz,1H)、4.03(m,3H)、3.91(t,J=5.2Hz,2H)
LCMS:C36H34FN8O7Pに対して741(M+H+)
1H NMR(600MHz、D2O)δ8.17(s,1H)、7.90(s,1H)、7.77(d,J=7.8Hz,1H)、7.62(s,1H)、7.58(s,1H)、7.26(dd,J1=8.4Hz,J2=8.4Hz,1H)、7.05(d,J=12.6Hz,1H)、6.97(d,J=7.8Hz,1H)、6.93(d,J=8.4Hz,1H)、5.04(m,1H)、4.73(m,2H)、4.60(m,2H)、4.13(dd,J1=8.4Hz,J2=8.4Hz,1H)、3.75(m,3H)、3.37(m,2H)
LCMS:C22H22FN8O7Pに対して561(M+H+)
1H NMR(600MHz、DMSO)δ8.51(s,1H)、8.18(s,1H)、8.04(s,1H)、7.99(d,J=9.0Hz,1H)、7.77(s,1H)、7.62(dd,J1=8.4Hz,J2=8.4Hz,1H)、7.55(d,J=13.8Hz,1H)、7.36(m,2H)、5.17(m,1H)、4.86(d,J=4.2Hz,2H)、4.29(dd,J1=9.0Hz,J2=9,0Hz,1H)、4.04(m,1H)、3.95(m,3H)、3.83(m,2H)、3.64(m,1H)、3.55(m,1H)
LCMS:C23H23FN8O5に対して511(M+H+)
1H NMR(400MHz、DMSO)δ8.53(s,1H)、8.20(d,J=1.2Hz,1H)、8.13(s,1H)、8.00(d,J=7.2Hz,1H)、7.77(d,J=1.2Hz,1H)、7.63(dd,J1=8.8Hz,J2=8.8Hz,1H)、7.55(dd,J1=13.2Hz,J2=2.0Hz,1H)、7.40(m,2H)、5.19(m,1H)、4.87(d,J=5.4Hz,2H)、4.29(dd,J1=9.2Hz,J2=9.2Hz,1H)、4.04(m,3H)、3.96(m,4H)、
LCMS:C22H22FN9O3に対して480(M+H+)
1H NMR(600MHz、DMSO−6)δ8.98(s,1H)、8.62(s,1H)、8.40(d,J=1.8Hz,1H)、8.14(d,J=9.0Hz,1H)、7.67(m,2H)、7.58(d,J=9Hz,1H)、7.46(dd,J1=9.0Hz,J2=2.4Hz,1H)、6.02(d,J=1.8Hz,1H)、4.93(m,1H)、4.22(dd,J1=9.0Hz,J2=9.0Hz 1H)、4.12(t,J=5.4Hz,2H)、3.88(dd,J=6.6Hz,1H)、3.46(m,4H)
LCMS:C21H21FN7O3に対して439(M+H+)
1H NMR(600MHz、DMSO)δ8.94(s,1H)、8.60(s,1H)、8.39(d,J=1.8Hz,1H)、8.13(d,J=9.0Hz,1H)、7.66(m,2H)、7.57(d,J=9.0Hz,1H)、7.46(dd,J1=8.4Hz,J2=2.4Hz,1H)、6.01(d,J=1.8Hz,1H)、4.92(m,1H)、4.21(dd,J1=9.0Hz,J2=9.0Hz,1H)、4.12(t,J=5.4Hz,2H)、3.88(dd,J1=9.0Hz,J2=6.6Hz,1H)、3.45(m,4H)、2.92(s,3H)
LCMS:C22H22FN7O3に対して452(M+H+)
1H NMR(600MHz、DMSO)δ8.05(s,1H)、8.40(s,1H)、8.00(m,2H)、7.63(m,2H)、7.44(d,J=7.8Hz,1H)、7.34(d,J=8.4Hz,1H)、6.60(s,1H)、6.01(s,1H)、4.92(m,1H)、4.66(s,1H)、4.36(m,2H)、4.20(dd,J1=8.4Hz,J2=8.4Hz,1H)、3.93(s,4H)、3.86(m,1H)、3.46(s,2H)
LCMS:C23H22FN7O5に対して496(M+H+)
1H NMR(600MHz、DMSO)δ8.55(s,1H)、8.41(d,J=0.6Hz,1H)、8.24(s,2H)、8.14(s,1H)、8.03(d,J=8.4Hz,1H)、7.65(m,2H)、7.45(dd,J1=9.0Hz,J2=2.4Hz,1H)、7.40(d,J=8.4Hz,1H)、6.01(d,J=1.2Hz,1H)、4.93(m,1H)、4.21(dd,J1=9.0Hz,J2=9.0Hz,1H)、4.00(m,4H)、3.87(dd,J1=9.0Hz,J2=6.6Hz,1H)、3.46(m,2H)、1.29(m,2H)
LCMS:C23H23FN8O4に対して495(M+H+)
1H NMR(600MHz、DMSO)δ8.52(s,1H)、8.41(d,J=1.2Hz,1H)、8.05(s,1H)、8.00(d,J=9.0Hz,1H)、7.64(m,2H)、7.44(d,J=7.2Hz,1H)、7.36(d,J=8.4Hz,1H)、6.61(s,1H)、6.01(d,J=1.2Hz,1H)、4.92(m,1H)、4.86(m,1H)、4.21(dd,J1=8.4Hz,J2=8.4Hz,1H)、4.03(m,2H)、3.84(m,5H)、3.47(m,2H)
LCMS:C24H24FN7O6に対して526(M+H+)
1H NMR(600MHz、DMSOd−6)δ8.95(m,1H)、8.72(d,J=1.8Hz,1H)、8.61(s,1H)、8.14(d,J=7.8Hz,1H)、7.69(m,2H)、7.55(d,J=8.4Hz,1H)、7.50(dd,J1=9.0Hz,J2=2.4Hz,1H)、6.41(d,J=1.8Hz,1H)、5.14(m,1H)、4.51(m,2H)、4.27(t,J=9.0Hz,1H)、3.99(m,3H)、3.39(m,2H)
LCMS:C21H20FN6O4に対して440(M+H+)
1H NMR(600MHz、CDCl3)δ8.46(s,1H)、8.17(d,J=1.8Hz,1H)、7.99(s,1H)、7.82(m,1H)、7.57(dd,J1=13.2Hz,J2=2.4Hz,1H)、7.43(t,J=9.0Hz,1H)、7.36(dd,J1=8.4Hz,J2=2.4Hz,1H)、6.87(d,J=8.4Hz,1H)、6.02(d,J=1.8Hz,1H)、5.06(m,1H)、4.61(dd,J1=11.4Hz,J2=3.6Hz,1H)、4.53(dd,J1=12.0Hz,J2=4.8Hz,1H)、4.21(t,J=9.0Hz,1H)、4.02(dd,J1=9.0Hz,J2=6.6Hz,1H)、3.94(t,J=5.4Hz,2H)、3.03(t,J=4.8Hz,2H)、2.85(s,3H)
LCMS:C22H22FN6O4に対して454(M+H+)
1H NMR(400MHz、DMSOd−6)δ8.72(d,J=1.6Hz,1H)、8.52(s,1H)、8.01(m,1H)、7.64(m,2H)、7.47(dd,J1=8.4Hz,J2=2.0Hz,1H)、7.35(d,J=8.8Hz,1H)、6.41(d,J=1.6Hz,1H)、5.13(m,1H)、4.64(t,J=6.0Hz,1H)、4.51(m,2H)、4.37(d,J=6.4Hz,2H)、4.26(t,J=9.2Hz,1H)、3.99(dd,J1=9.2Hz,J2=6.0Hz,1H)、3.93(m,4H)
LCMS:C23H22FN6O6に対して498(M+H+)
1H NMR(400MHz、DMSOd−6)δ8.72(d,J=1.6Hz,1H)、8.52(s,1H)、8.01(m,1H)、7.64(m,2H)、7.47(dd,J1=8.4Hz,J2=2.0Hz,1H)、7.35(d,J=8.8Hz,1H)、6.41(d,J=1.6Hz,1H)、5.13(m,1H)、4.64(t,J=6.0Hz,1H)、4.51(m,2H)、4.37(d,J=6.4Hz,2H)、4.26(t,J=9.2Hz,1H)、3.99(dd,J1=9.2Hz,J2=6.0Hz,1H)、3.93(m,4H)
LCMS:C23H22FN6O6に対して498(M+H+)
1H NMR(600MHz、DMSOd−6)δ8.72(d,J=1.8Hz,1H)、8.54(s,1H)、8.18(t,J=5.4Hz,2H)、8.14(s,1H)、8.04(d,J=9.0Hz,1H)、7.65(m,2H)、7.48(dd,J1=9.0Hz,J2=2.4Hz,1H)、7.41(d,J=9.0Hz,1H)、6.41(d,J=1.8Hz,1H)、5.13(m,1H)、4.53(dd,J1=11.4Hz,J2=3.0Hz,1H)、4.49(dd,J1=11.4Hz,J2=6.0Hz,1H)、4.26(t,J=9.0Hz,1H)、4.03(m,2H)、3.98(m,5H)
LCMS:C23H23FN7O5に対して497(M+H+)
1H NMR(600MHz、CDCl3)δ8.50(s,1H)、8.18(d,J=1.8Hz,1H)、7.90(s,2H)、7.89( m,1H)、7.60(dd,J1=13.2Hz,J2=2.4Hz,1H)、7.44(t,J=8.4Hz,1H)、7.34(dd,J1=8.4Hz,J2=2.4Hz,1H)、6.97(d,J=9.0Hz,1H)、6.02(d,J=1.8Hz,1H)、5.33(t,J=6.6Hz,1H)、5.07(m,1H)、4.61(dd,J1=11.4Hz,J2=3.6Hz,1H)、4.53(dd,J1=12.4Hz,J2=4.8Hz,1H)、4.22(t,J=9.0Hz,1H)、4.12(m,1H)、4.01(m,3H)、3.94(m,1H)、3.89(m,1H)、1.56(s,3H)、1.48(s,3H)
LCMS:C27H28FN6O7に対して568(M+H+)
1H NMR(600MHz、DMSOd−6)δ8.72(d,J=1.8Hz,1H)、8.53(s,1H)、8.05(s,1H)、8.01(m,1H)、7.66(m,2H)、7.48(m,1H)、7.37(d,J=9.6Hz,1H)、6.41(d,J=1.8Hz,1H)、5.12(m,1H)、4.86(m,1H)、4.67(m,2H)、4.51(m,2H)、4.26(t,J=9.0Hz,1H)、4.06(m,1H)、4.00(m,2H)、3.84(m,2H)、3.65(m,1H)、3.56(m,1H)
LCMS:C24H24FN6O7に対して528(M+H+)
1H NMR(600MHz、DMSOd−6)δ12.43(s,1H)、8.72(d,J=1.8Hz,1H)、8.46(s,1H)、7.94(m,2H)、7.65(m,2H)、7.46(m,1H)、7.19(d,J=9.0Hz,1H)、6.42(d,1.8Hz,1H)、5.13(m,1H)、4.51(dd,J1=11.4Hz,J2=8.4Hz,1H)、4.48(t,J=6.0Hz,1H)、4.26(t,J=8.4Hz,1H)、3.99(m,1H)、3.87(t,J=4.8Hz,2H)、3.70(s,3H)、3.23(t,J=4.8Hz,2H)
LCMS:C23H22FN6O6に対して498(M+H+)
1H NMR(600MHz、CD3OD)δ8.57(s,1H)、8.32(s,1H)、7.85〜7.81(m,2H)、7.61(m,1H)、7.50(m,2H)、7.35(m,1H)、4.18(m,2H)、4.11(m,2H)、3.91(m,2H)、3.87(m,1H)、3.57(m,2H)、1.97(s,3H)
LCMS:C21H21FN6O4に対して441(M+H+)
1H NMR(600MHz、DMSOd−6)δ8.24(s,1H)、7.71(d,J=9.0Hz,1H)、7.55(m,1H)、7.42(m,1H)、7.37(d,J=9.0Hz,1H)、7.26(d,J=9.0Hz,1H)、6.89(s,1H)、6.81(s,1H)、4.76(m,1H)、4.16(m,2H)、3.77(m,2H)、3.44〜3.37(m,4H)、1.84(s,3H)
LCMS:C20H21FN6O3に対して413(M+H+)
1H NMR(600MHz、DMSOd−6)δ8.35(s,1H)、8.26(t,J=6.0Hz,1H)、7.85(d,J=8.4Hz,1H)、7.61〜7.57(m,2H)、7.44〜7.39(m,2H)、5.32(brs,1H)、4.76(m,1H)、4.41(brs,1H)、4.18(m,1H)、4.06(t,J=5.4Hz,1H)、3.84〜3.76(m,2H)、3.42(t,J=5.4Hz,1H)、3.35(m,2H)、1.84(s,3H)
LCMS:C22H23FN6O5に対して471(M+H+)
1H NMR(600MHz、CDCl3)δ8.43(m,2H)、7.71(d,J=9.0Hz,1H)、7.54(dd,J1=12.6Hz,J2=2.4Hz,1H)、7.39(t,J=8.4Hz,1H)、7.28(dd,J1=9Hz,J2=2.4Hz,1H)、6.70(d,J=9.0Hz,1H)、6.00(t,J=6.0Hz,1H)、4.82(m,1H)、4.66(dd,J1=17.4Hz,J2=2.4Hz,1H)、4.55(m,1H)、4.13(dd,J1=17.4Hz,J2=2.4Hz,1H)、4.09(t,J=9.0Hz,1H)、3.81(m,1H)、3.77〜3.71(m,2H)、3.63(m,1H)、2.98(m,1H)、2.90(m,1H)、2.26(t,J=2.4Hz,1H)、2.04(s,3H)
LCMS:C23H23FN6O3に対して451(M+H+)
1H NMR(600MHz、CDCl3)δ8.30(s,1H)、7.71(d,J=9.0Hz,1H)、7.50(d,J=12.6Hz,1H)、7.40(t,J=8.4Hz,1H)、7.35(d,J=8.4Hz,1H)、7.25(m,1H)、6.73(s,1H)、4.80(m,1H)、4.11〜4.06(m,3H)、3.80(m,1H)、3.73(m,1H)、3.62(m,1H)、3.44(t,J=4.8Hz,2H)、3.20(q,J=7.2Hz,2H)、1.21(t,J=7.2Hz,2H)
LCMS:C22H25FN6O3に対して441(M+H+)
1H NMR(600MHz、DMSOd−6)δ8.53(s,1H)、8.50(s,1H)、8.28(t,J=5.4Hz,1H)、8.00(d,J=7.8Hz,1H)、7.63(m,2H)、7.43(d,J=9.0Hz,1H)、7.29(d,J=9.0Hz,1H)、4.76(m,1H)、4.18(t,J=9.0Hz,1H)、4.13(t,J=4.8Hz,2H)、3.88(t,J=4.8Hz,2H)、3.79(m,1H)、3.44(t,J=4.8Hz,2H)、1.84(s,3H)
LCMS:C20H20FN5O4に対して414(M+H+)
1H NMR(600MHz、DMSOd−6)δ8.52(s,1H)、7.99(t,J=9.6Hz,1H)、7.64(m,2H)、7.47(m,2H)、7.29(d,J=9.0Hz,1H)、5.28(t,J=6.0Hz,1H)、4.75(m,1H)、4.22(m,1H)、4.14(m,3H)、3.89(m,2H)、3.70(m,1H)、3.57(m,1H)
LCMS:C18H17FN4O4に対して373(M+H+)
1H NMR(600MHz、DMSOd−6)δ8.52(s,1H)、8.50(s,1H)、8.00(dd,J1=9.0Hz,J2=1.8Hz,1H)、7.64(t,J=9.0Hz,1H)、7.62(dd,J1=13.2Hz,J2=2.4Hz,1H)、7.55(t,J=5.4Hz,1H)、7.43(dd,J1=8.4Hz,J2=1.8Hz,1H)、7.29(d,J=8.4Hz,1H)、4.77(m,1H)、4.18(t,J=9.0Hz,1H)、4.11(t,J=4.2Hz,2H)、3.88(m,2H)、3.81(m,1H)、3.54(s,3H)、3.33(m,2H)
LCMS:C20H20FN5O5に対して430(M+H+)
1H NMR(600MHz、DMSOd−6)δ8.52(s,1H)、8.49(s,1H)、8.19(s,1H)、7.99(d,J=8.4Hz,1H)、7.78(s,1H)、7.62(t,J=8.4Hz,1H)、7.55(dd,J1=13.2Hz,J2=2.4Hz,1H)、7.38(dd,J1=8.4Hz,J2=2.4Hz,1H)、7.29(d,J=8.4Hz,1H)、5.18(m,1H)、4.86(m,1H)、4.29(t,J=9.0Hz,1H)、4.11(t,J=4.8Hz,2H)、3.95(m,1H)、3.88(t,J=4.8Hz,2H)
LCMS:C20H18FN7O3に対して424(M+H+)
1H NMR(600MHz、DMSO)δ8.55(s,1H)、8.50(s,1H)、8.39(d,J=1.8Hz,1H)、8.00(d,J=10.2Hz,1H)、7.63(m,2H)、7.44(dd,J1=9.0Hz,J2=2.4Hz,1H)、7.29(d,J=8.4Hz,1H)、6.01(d,J=1.8Hz,1H)、4.92(m,1H)、4.21(dd,J1=8.4Hz,J2=8.4Hz,1H)、4.12(t,J=7.2Hz,2H)、3.88(m,3H)、3.47(m,2H)
LCMS:C21H19FN6O4に対して439(M+H+)
1H NMR(600MHz、CDCl3)δ8.72(m,1H)、7.88(dd,J1=8.4Hz,J2=3.6Hz,1H)、7.59(dd,J1=12.6Hz,J2=2.4Hz,1H)、7.44(dd,J1=8.4Hz,J2=8.4Hz,1H)、7.33(dd,J1=8.4Hz,J2=2.4Hz,1H)、7.08(d,J=8.4Hz,1H)、6.12(t,J=6Hz,1H)、4.83(m,1H)、4.21(t,J=4.8Hz,2H)、4.10(dd,J=9.0Hz,1H)、3.93(t,J=3.6Hz,2H)、3.85(dd,J=6.6Hz,1H)、3.75〜3.65(m,J=6.6Hz,2H)
LCMS:C21H22FN5O4に対して428(M+H+)
1H NMR(600MHz、DMSOd−6)δ8.55(s,1H)、7.86(m,1H)、7.56(dd,J1=12.6Hz,J2=1.8Hz,1H)、7.43(t,J=8.4Hz,1H)、7.33(dd,J1=8.4Hz,J2=1.8Hz,1H)、7.05(d,J=8.4Hz,1H)、5.13(m,1H)、4.79(m,1H)、4.18(t,J=4.8Hz,2H)、4.08(t,J=9.0Hz,1H)、3.90(t,J=4.8Hz,2H)、3.85(t,J=7.8Hz,1H)、3.67(s,3H)、3.63(m,1H)、3.55(m,1H)、2.10(s,3H)
LCMS:C21H22FN5O5に対して444(M+H+)
1H NMR(600MHz、DMSOd−6)δ8.77(s,1H)、8.27(t,J=6.0Hz,1H)、8.04(dd,J1=7.2Hz,J2=1.8Hz,1H)、7.96(d,J=9.0Hz,1H)、7.71(t,J=8.4Hz,1H)、7.66(dd,J1=13.2Hz,J2=2.4Hz,1H)、7.47(dd,J1=8.4Hz,J2=2.4Hz,1H)、7.40(t,J=3.6Hz,1H)、4.78(m,1H)、4.19(t,J=8.4Hz,1H)、3.88(t,J=4.8Hz,2H)、3.80(dd,J1=9.0Hz,J2=6.0Hz,1H)、3.47(dd,J1=8.4Hz,J2=3.6Hz,2H)、3.44(t,J=4.8Hz,2H)、1.84(s,3H)
LCMS:C20H20FN5O4に対して414(M+H+)
1H NMR(400MHz、DMSOd−6)δ8.77(s,1H)、8.05(d,J=8.4Hz,1H)、7.96(d,J=8.0Hz,1H)、7.72(t,J=8.8Hz,1H)、7.66(dd,J1=13.6Hz,J2=2.0Hz,1H)、7.56(t,J=5.6Hz,1H)、7.47(dd,J1=8.4Hz,J2=2.0Hz,1H)、7.40(m,1H)、4.78(m,1H)、4.19(t,J=9.0Hz,1H)、3.88(t,J=4.6Hz,2H)、3.84(dd,J1=8.8Hz,J2=6.0Hz,1H)、3.55(s,3H)、3.48(m,4H)
LCMS:C20H20FN5O5に対して430(M+H+)
1H NMR(600MHz、DMSOd−6)δ8.77(s,1H)、8.19(s,1H)、8.04(d,J=8.4Hz,1H)、7.95(d,J=8.4Hz,1H)、7.78(s,1H)、7.70(t,J=9.0Hz,1H)、7.60(dd,J1=13.8Hz,J2=2.4Hz,1H)、7.42(dd,J1=8.4Hz,J2=2.4Hz,1H)、7.40(t,J=2.4Hz,1H)、5.19(m,1H)、4.87(m,1H)、4.31(t,J=9.0Hz,1H)、3.97(m,1H)、3.88(t,J=4.8Hz,2H)、3.47(m,2H)
LCMS:C20H18FN7O3に対して424(M+H+)
1H NMR(600MHz、DMSO)δ9.08(s,1H)、8.89(s,1H)、8.40(d,J=1.8Hz,1H)、8.20(dd,J1=8.4Hz,J2=1.2Hz,1H)、8.13(d,J=8.4Hz,1H)、7.75(dd,J1=8.4Hz,J2=8.4Hz,1H)、7.69(dd,J1=13.8Hz,J2=2.4Hz,1H)、7.50(dd,J1=8.4Hz,J2=1.8Hz,1H)、6.01(d,J=1.8Hz,1H)、4.94(m,1H)、4.23(dd,J1=9.0Hz,J2=9.0Hz,1H)、4.13(t,J=4.2Hz,2H)、3.90(dd,J1=9.0Hz,J2=6.6Hz,1H)、3.60(t,J=4.2Hz,2H)、3.47(m,2H)
LCMS:C21H19FN6O4に対して439(M+H+)
1H NMR(600MHz、DMSOd−6)δ8.78(s,1H)、8.72(d,J=1.8Hz,1H)、8.05(d,J=8.4Hz,1H)、7.74(d,J=8.4Hz,1H)、7.70(dd,J1=15.6Hz,J2=2.4Hz,1H)、7.52(dd,J1=9.0Hz,J2=2.4Hz,1H)、7.43(m,1H)、6.42(d,J=1.8Hz,1H)、5.14(m,1H)、4.50(m,2H)、4.27(t,J=9.0Hz,1H)、4.00(dd,J1=9.6Hz,J2=6.0Hz,1H)、3.88(t,J=4.8Hz,2H)、3.47(m,2H)
LCMS:C21H19FN5O5に対して441(M+H+)
1H NMR(600MHz、CDCl3)δ8.80(s,1H)、7.93(d,J=8.4Hz,1H)、7.72(d,J=7.8Hz,1H)、7.61(dd,J1=12.6Hz,J2=2.4Hz,1H)、7.47(t,J=9.0Hz,1H)、7.33(dd,J1=9.0Hz,J2=2.4Hz,1H)、6.03(m,1H)、4.83(m,1H)、4.18(t,J=9.0Hz,1H)、4.10(t,J=9.0Hz,1H)、3.84(dd,J1=8.4Hz,J2=6.6Hz,1H)、3.74(m,1H)、3.68(m,3H)、3.52(t,J=4.8Hz,2H)、2.94(s,3H)、2.04(s,3H)
LCMS:C21H22FN5O4に対して428(M+H+)
1H NMR(600MHz、CDCl3)δ8.81(s,1H)、7.93(d,J=7.8Hz,1H)、7.72(d,J=7.8Hz,1H)、7.60(dd,J1=13.2Hz,J2=1.8Hz,1H)、7.47(t,J=8.4Hz,1H)、7.35(dd,J1=9.0Hz,J2=2.4Hz,1H)、5.13(m,1H)、4.82(m,1H)、4.17(t,J=4.8Hz,2H)、4.11(t,J=9.0Hz,1H)、3.87(t,J=7.8Hz,1H)、3.70(s,3H)、3.65(m,1H)、3.60(m,1H)、3.51(t,J=7.8Hz,2H)、2.94(s,3H)
LCMS:C21H22FN5O5に対して444(M+H+)
1H NMR(400MHz、DMSOd−6)δ8.82(s,1H)、8.06(d,J=8.4Hz,1H)、7.69(m,1H)、7.63(d,J=8.4Hz,1H)、7.51(m,2H)、5.27(t,J=6.0Hz,1H)、4.76(m 1H)、4.15(t,J=9.2Hz,1H)、4.00(t,J=4.8Hz,2H)、3.90(dd,J1=8.8Hz,J2=6.1Hz,1H)、3.70(m,1H)、3.59(m,1H)、3.42(t,J=4.4Hz,2H)、2.80(s,1H)
LCMS:C19H19FN4O4に対して444(M+H+)
実施例1〜71に従って合成されたオキサゾリジノン誘導体の抗細菌活性を評価するために、以下の方法を用いてin vitro活性試験を行った。
スタフィロコッカス・アウレウス(Staphylococcus aureus)、メチシリン耐性スタフィロコッカス・アウレウス(Staphylococcus aureus)、スタフィロコッカス・エピデルミディス(Staphylococcus epidermidis)、メチシリン耐性スタフィロコッカス・エピデルミディス(Staphylococcus epidermidis)、エンテロコッカス・フェカリス(Enterococcus faecalis)、バンコマイシン耐性エンテロコッカス・フェカリス(Enterococcus faecalis)、リネゾリド耐性およびバンコマイシン耐性エンテロコッカス・フェカリス(Enterococcus faecalis)、エンテロコッカス・フェシウム(Enterococcus faecium)、バンコマイシン耐性エンテロコッカス・フェシウム(Enterococcus faecium)、リネゾリド耐性およびバンコマイシン耐性エンテロコッカス・フェシウム(Enterococcus faecium)、およびモラクセラ・カタラーリス(Moraxella catarrhalis)を含む12種の株の活性を測定した。また、結果を以下の表1に示す。
10240μg/mLの試験材料(即ち、実施例1〜71のオキサゾリジノン誘導体)をそれぞれDMSO中に溶解させ、それぞれの得られた溶液を二倍段階希釈に付し、次いで、無菌三重蒸留水で20倍に希釈した。抗細菌試験での試験材料の最終濃度は、0.063μg/mL(最小)〜128μg/mL(最大)あり、賦形剤として使用したDMSOの最終濃度は、2.5%(V/V)であった。以下の式Bにより表されるリネゾリド(Pfizer製造)を対照として使用し、その細菌活性を試験材料のものと比較した。結果を以下の表1に示す。
Claims (7)
- 下記式(1):
Rは、下記の基:
R1は、水素、C1〜C6アルキルまたはC3〜C6シクロアルキルであり、
R2は、水素、C1〜C6アルキルまたは(CH2)mC(=O)R21である(R21は、水素、(CH2)nNHR211(R211は、水素またはC1〜C6アルキルである)、CH2OHまたはCH(OH)CH2OHである)(mおよびnは、それぞれ独立して、0〜3の整数である))
よりなる群から選択されるヘテロ環式基であり、
Qは、OR3、NHR3または下記の基:
により表される新規なオキサゾリジノン誘導体、そのプロドラッグ、その水和物、その溶媒和物、その異性体またはその薬学的に許容可能な塩。 - 抗生物質の医薬組成物であって、
(a)治療上有効量の、請求項1〜5のいずれかに記載の新規なオキサゾリジノン誘導体、そのプロドラッグ、その水和物、その溶媒和物、その異性体またはその薬学的に許容可能な塩、および
(b)薬学的に許容可能な担体、希釈剤、賦形剤またはそれらの組み合わせ
を含む医薬組成物。 - 有効量の、請求項1に記載の式(1)により表される新規なオキサゾリジノン誘導体、そのプロドラッグ、その水和物、その溶媒和物、その異性体またはその薬学的に許容可能な塩を使用する抗生物質治療法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020110028559A KR101653570B1 (ko) | 2011-03-30 | 2011-03-30 | 신규한 옥사졸리디논 유도체 및 이를 함유하는 의약 조성물 |
KR10-2011-0028559 | 2011-03-30 | ||
PCT/KR2012/002314 WO2012134188A2 (ko) | 2011-03-30 | 2012-03-29 | 신규한 옥사졸리디논 유도체 및 이를 함유하는 의약 조성물 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2014510751A true JP2014510751A (ja) | 2014-05-01 |
JP6072764B2 JP6072764B2 (ja) | 2017-02-01 |
Family
ID=46932138
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014502469A Expired - Fee Related JP6072764B2 (ja) | 2011-03-30 | 2012-03-29 | 新規なオキサゾリジノン誘導体およびそれを含む医薬組成物 |
Country Status (12)
Country | Link |
---|---|
US (1) | US8846669B2 (ja) |
EP (2) | EP2692727A4 (ja) |
JP (1) | JP6072764B2 (ja) |
KR (1) | KR101653570B1 (ja) |
CN (1) | CN103476772B (ja) |
AU (1) | AU2012237067B2 (ja) |
BR (1) | BR112013024497A2 (ja) |
CA (1) | CA2831799A1 (ja) |
MX (1) | MX337409B (ja) |
RU (1) | RU2617408C2 (ja) |
WO (1) | WO2012134188A2 (ja) |
ZA (1) | ZA201307216B (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104774198A (zh) * | 2014-01-15 | 2015-07-15 | 上海美迪西生物医药有限公司 | 一种新噁唑烷酮类化合物及其制备方法 |
CN106928214A (zh) * | 2014-09-17 | 2017-07-07 | 博瑞生物医药(苏州)股份有限公司 | 一种噁唑烷酮类化合物及其中间体的制备方法 |
WO2016201168A1 (en) * | 2015-06-10 | 2016-12-15 | Forum Pharmceuticals Inc. | Oxadiazine compounds and methods of use thereof |
CN106045934A (zh) * | 2015-10-27 | 2016-10-26 | 博瑞生物医药(苏州)股份有限公司 | 一种合成泰地唑胺的中间体的晶型 |
CN107722056A (zh) * | 2017-10-31 | 2018-02-23 | 重庆华邦胜凯制药有限公司 | 磷酸特地唑胺的制备方法 |
CN115650908A (zh) * | 2022-09-26 | 2023-01-31 | 南京康立瑞生物科技有限公司 | 一种5-溴-2氰基吡啶的制备方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001094342A1 (en) * | 2000-06-05 | 2001-12-13 | Dong A Pharm. Co., Ltd. | Novel oxazolidinone derivatives and a process for the preparation thereof |
WO2004056816A1 (en) * | 2002-12-19 | 2004-07-08 | Astrazeneca Ab | Antibacterial oxazolidinones |
WO2004056819A1 (en) * | 2002-12-19 | 2004-07-08 | Astrazeneca Ab | Oxazolidinone derivatives as antibacterial agents |
WO2005116024A1 (en) * | 2004-05-25 | 2005-12-08 | Astrazeneca Ab | 3- (4- (2-dihydroisoxazol-3-ylpyridin-5-yl) phenyl) -5-triazol-1-ylmethyloxazolidin-2-one derivaives as mao inhibitors for the treatment of bacterial infections |
WO2010036000A2 (en) * | 2008-09-24 | 2010-04-01 | Legochem Bioscience Ltd. | Novel oxazolidinone derivatives with cyclic amidoxime or cyclic amidrazone and pharmaceutical compositions thereof |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES533097A0 (es) | 1983-06-07 | 1985-08-01 | Du Pont | Un procedimiento para la preparacion de nuevos derivados del amino-metil-oxooxazolidinil-benzeno. |
KR100731469B1 (ko) * | 2000-06-05 | 2007-06-21 | 동아제약주식회사 | 피리딘 고리를 포함하는 옥사졸리디논 유도체 및 그의제조방법 |
TW200500360A (en) * | 2003-03-01 | 2005-01-01 | Astrazeneca Ab | Hydroxymethyl compounds |
KR100854211B1 (ko) * | 2003-12-18 | 2008-08-26 | 동아제약주식회사 | 신규한 옥사졸리디논 유도체, 그의 제조방법 및 이를유효성분으로 하는 항생제용 약학 조성물 |
EP1799677A1 (en) * | 2004-10-08 | 2007-06-27 | Ranbaxy Laboratories Limited | Oxazolidinone derivatives as antimicrobials |
WO2007023507A2 (en) * | 2005-06-20 | 2007-03-01 | Wockhardt Limited | Oxazolidinones bearing antimicrobial activity composition and methods of preparation |
KR100872059B1 (ko) * | 2007-02-21 | 2008-12-05 | 주식회사 레고켐 바이오사이언스 | 아미독심 또는 하이드록사마이드 기를 가지는 신규한옥사졸리디논 유도체 및 이를 함유하는 의약 조성물 |
KR100870432B1 (ko) | 2007-04-18 | 2008-11-25 | 주식회사 하이닉스반도체 | 트리밍 테스트모드 및 노말 테스트모드를 갖는반도체메모리소자 |
KR101037051B1 (ko) * | 2009-07-08 | 2011-05-26 | 주식회사 레고켐 바이오사이언스 | (s)-5-클로로-n-((3-(4-(5,6-다이하이드로-4h-1,2,4-옥사다이아진-3-일)페닐)-2-옥소옥사졸리딘-5-일)메틸)싸이오펜-2-카르복사미드 유도체의 제조방법 |
-
2011
- 2011-03-30 KR KR1020110028559A patent/KR101653570B1/ko active IP Right Grant
-
2012
- 2012-03-29 AU AU2012237067A patent/AU2012237067B2/en not_active Ceased
- 2012-03-29 US US14/008,702 patent/US8846669B2/en not_active Expired - Fee Related
- 2012-03-29 BR BR112013024497-6A patent/BR112013024497A2/pt not_active IP Right Cessation
- 2012-03-29 JP JP2014502469A patent/JP6072764B2/ja not_active Expired - Fee Related
- 2012-03-29 EP EP12764499.5A patent/EP2692727A4/en not_active Ceased
- 2012-03-29 EP EP18167465.6A patent/EP3372598A1/en not_active Withdrawn
- 2012-03-29 RU RU2013143800A patent/RU2617408C2/ru not_active IP Right Cessation
- 2012-03-29 MX MX2013011272A patent/MX337409B/es active IP Right Grant
- 2012-03-29 CN CN201280016771.9A patent/CN103476772B/zh not_active Expired - Fee Related
- 2012-03-29 WO PCT/KR2012/002314 patent/WO2012134188A2/ko active Application Filing
- 2012-03-29 CA CA2831799A patent/CA2831799A1/en not_active Abandoned
-
2013
- 2013-09-26 ZA ZA2013/07216A patent/ZA201307216B/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001094342A1 (en) * | 2000-06-05 | 2001-12-13 | Dong A Pharm. Co., Ltd. | Novel oxazolidinone derivatives and a process for the preparation thereof |
WO2004056816A1 (en) * | 2002-12-19 | 2004-07-08 | Astrazeneca Ab | Antibacterial oxazolidinones |
WO2004056819A1 (en) * | 2002-12-19 | 2004-07-08 | Astrazeneca Ab | Oxazolidinone derivatives as antibacterial agents |
WO2005116024A1 (en) * | 2004-05-25 | 2005-12-08 | Astrazeneca Ab | 3- (4- (2-dihydroisoxazol-3-ylpyridin-5-yl) phenyl) -5-triazol-1-ylmethyloxazolidin-2-one derivaives as mao inhibitors for the treatment of bacterial infections |
WO2010036000A2 (en) * | 2008-09-24 | 2010-04-01 | Legochem Bioscience Ltd. | Novel oxazolidinone derivatives with cyclic amidoxime or cyclic amidrazone and pharmaceutical compositions thereof |
Also Published As
Publication number | Publication date |
---|---|
CA2831799A1 (en) | 2012-10-04 |
KR20120110600A (ko) | 2012-10-10 |
EP2692727A4 (en) | 2014-10-15 |
CN103476772A (zh) | 2013-12-25 |
RU2617408C2 (ru) | 2017-04-25 |
US20140179691A1 (en) | 2014-06-26 |
AU2012237067A1 (en) | 2013-10-03 |
US8846669B2 (en) | 2014-09-30 |
CN103476772B (zh) | 2016-03-30 |
MX2013011272A (es) | 2014-03-21 |
KR101653570B1 (ko) | 2016-09-02 |
JP6072764B2 (ja) | 2017-02-01 |
WO2012134188A3 (ko) | 2013-01-10 |
ZA201307216B (en) | 2014-12-23 |
MX337409B (es) | 2016-03-02 |
AU2012237067B2 (en) | 2016-07-28 |
WO2012134188A2 (ko) | 2012-10-04 |
EP3372598A1 (en) | 2018-09-12 |
EP2692727A2 (en) | 2014-02-05 |
RU2013143800A (ru) | 2015-05-10 |
BR112013024497A2 (pt) | 2018-06-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6072764B2 (ja) | 新規なオキサゾリジノン誘導体およびそれを含む医薬組成物 | |
US6689779B2 (en) | Oxazolidinone derivatives and a process for the preparation thereof | |
RU2414469C2 (ru) | Новые производные оксазолидинона | |
JP2004518677A (ja) | 抗菌性キノロン誘導体および細菌感染を治療するためのその使用 | |
US10519125B2 (en) | Flavagline derivatives | |
US20060293307A1 (en) | Oxazolidinone derivatives as antimicrobials | |
KR100872059B1 (ko) | 아미독심 또는 하이드록사마이드 기를 가지는 신규한옥사졸리디논 유도체 및 이를 함유하는 의약 조성물 | |
JP5662940B2 (ja) | 新規な抗微生物薬 | |
EP1786805A1 (en) | Oxazolidinone compounds and compositions and methods related thereto | |
JP2004196678A (ja) | ピラゾール系誘導体 | |
WO2014161412A1 (zh) | 一类三环喹诺酮衍生物及其制备方法和用途 | |
WO2022005976A2 (en) | Antibacterial picolinamide compounds | |
KR100948345B1 (ko) | 신규한 옥사졸리디논 유도체, 이의 제조방법 및 이를함유하는 의약 조성물 | |
KR20030027094A (ko) | 신규 에스테르 또는 아미드 유도체 | |
WO2005082900A2 (en) | Oxazolidinone amidoximes as antibacterial agents | |
HUT65885A (en) | Process for preparing heterocyclyl-phenoxyalkyl-piperidinylpyridazines and pharmaceutical compositions containing them | |
KR100856745B1 (ko) | 헤테로 고리 및 헤테로아로마틱 고리가 치환 또는 융합된피리딘을 포함하는 옥사졸리디논 유도체 및 그의 제조방법 | |
WO2009077485A2 (en) | 1(2)h-tetrazol-5-yl-phenyl-oxazolidinones as antibacterial agents | |
SG185169A1 (en) | Biphenyl oxazolidinone antibiotic | |
JP2006052139A (ja) | プロリン誘導体 | |
JP2006052140A (ja) | プロリン誘導体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150306 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20150702 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20150818 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20151029 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20151201 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160229 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20160726 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161109 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20161118 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20161206 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20161228 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6072764 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |